期刊文献+

COL6A3基因在胃癌中的表达及临床意义

Clinical significance of COL6A3 expression in gastric cancer
下载PDF
导出
摘要 背景从分子水平探析胃癌(gastric cancer, GC)病理机制对改善患者预后至关重要.目前, COL6A3在GC中的表达情况及临床意义鲜有报道.目的研究COL6A3基因在GC中的表达情况和临床意义,并探究可能的作用机制.方法收集GC相关生物大数据,对肿瘤样本的基因表达谱数据及其对应的临床信息进行回顾性分析和生存分析;采用基因集富集分析方法探讨COL6A3在GC中可能的作用机制.结果 COL6A3在GC中表达明显升高(P <0.0001),且具有较大诊断价值(AUC=0.9516). COL6A3高表达与T分期显著相关(P=0.001), COL6A3高表达的GC浸润深度更大. COL6A3高表达患者的预后明显差于低表达患者(P=0.0018). COL6A3高表达样本中,富集了多个肿瘤相关通路的基因集(n=68).结论 COL6A3高表达与GC的发生发展相关,具有较大的临床意义. BACKGROUND Elucidating the molecular mechanism of gastric cancer(GC)is of great significance,especially for improving the prognosis,and few studies have focused on the clinical significance of COL6A3 expression in GC.AIM To analyze the clinical significance of COL6A3 expression in GC,and to identify the potential role of COL6A3 in GC.METHODS The biological big data of GC were collected,and retrospective analysis and survival analysis were conducted on the expression profile of COL6A3 in tumor samples and its relationship with clinical data.Gene set enrichment analysis was used to identify the potential role of COL6A3 in GC.RESULTS COL6A3 was highly expressed in GC(P<0.0001)with good diagnostic value(AUC=0.9516).High COL6A3 expression was associated with deeper tumor invasion(P=0.001).Patients with high expression of COL6A3 showed a poorer prognosis than those with low expression(P=0.0018).The tumor-related gene sets were enriched in the samples with high COL6A3 expression.CONCLUSION The high expression of COL6A3 is related to the occurrence and development of GC.
作者 韩一帆 朱少俊 Yi-Fan Han;Shao-Jun Zhu(Department of General Surgery,the Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang Province,China)
出处 《世界华人消化杂志》 CAS 2019年第5期293-298,共6页 World Chinese Journal of Digestology
关键词 胃癌 COL6A3 表达水平 临床意义 Gastric cancer COL6A3 Expression Clinical significance
  • 相关文献

参考文献2

二级参考文献28

  • 1肖波.遗传性肌肉疾病的研究现状及展望[J].中华神经科杂志,2007,40(4):217-219. 被引量:3
  • 2Bertini E, D'Amieo A, Gualandi F, et al. Congenital muscular dystrophies, a brief review[J]. Semin Pediatr Neurol, 2011, 18: 277-288.
  • 3Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population[J]. Brain, 2009, 132 (Pt 11) : 3175- 3186.
  • 4Bodi K, Perera AG, Adams PS, et al. Comparison of commercially available target enrichment methods for next- generation sequencing[J]. J Biomol Tech,2013, 24:73-86.
  • 5I.ampe AK, Dunn DM, yon Niederhausern AC, et al. Automated genomic sequence analysis of the three collagen Ⅵ genes: applications to Ullrich congenital muscular dystrophy and Bethlemmyopathy[J]. J MedGenet, 2005, 42: 108-120.
  • 6Bertini E, Pepe G. Collagen type Ⅵ and related disorders: Bethlem myopathy and Ullrich scleroatonic muscular dystrophy [J]. EurJ Paediatr Neurol,2002, 6:193-198.
  • 7Demir E, Sabatelli P, Allamand V, et al. Mutations in COL6A3 cause severe and mild phenotypes of ullrich congenital muscular dystrophy[J]. AmJ HumGenet, 2002, 70: 1446-1458.
  • 8Baker NL, MOrgelin M, Pace RA, et al. Molecular consequences of dominant Bethlem myopathy collagen Ⅵ mutations. Ann Neurol, 2007, 62:390-405.
  • 9Brinas L, Richard P.. Quijano-Roy S, et al. Early onset collagen Ⅵ myopathies: genetic and clinical correlations. Ann Neurol, 2010, 68: 511-520.
  • 10Baker NL, Morgelin M, Pace RA, et ai. Molecular consequences of dominant Bethlem myopathy collagen Ⅵ mutations. Ann Neurol, 2007, 62: 390-405.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部